Drug Profile
Research programme: CNS biotherapeutics - Axial Biotherapeutics
Alternative Names: AB-4000 seriesLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator California Institute of Technology/CalTech
- Developer Axial Therapeutics; Parkinsons Institute and Clinical Center
- Class Antiparkinsonians; Bacteria; Behavioural disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autistic disorder; Parkinson's disease
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Autistic-disorder in USA
- 28 Jul 2022 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 22 Jun 2018 Axial Biotherapeutics enters into an R&D agreement with Parkinson’s Institute and Clinical Center.